Recombinant human granulocyte-colony stimulating factor: In vitro and in vivo effects on myelopoiesis

K. Welte, M. A. Bonilla, J. L. Gabrilove, A. P. Gillio, G. K. Potter, M. A. Moore, R. J. O'Reilly, T. C. Boone, L. M. Souza

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


The results presented in this paper demonstrate that recombinant human granulocyte-colony stimulating factor (rhG-CSF) is a potent myelopoetic growth and differentiation factor in vivo. RhG-CSF was able to shorten the time period of neutrophil recovery in both cyclophosphamide (CY)-induced myelosuppression and following bone marrow transplantation (BMT) in primates. Its ability to significantly shorten the period of chemotherapy-induced bone marrow hypoplasia may allow clinicians to increase the frequency or dosage of chemotherapeutic agents. In addition, the increase in absolute numbers of functionally active neutrophils may have a profound effect on the rate and severity of neutropenia-related sepsis. Furthermore, the activities reported here indicate a potential role for rhG-CSF in the treatment of patients with myelodysplastic syndrome, congential agranulocytosis, radiation-induced myelosuppression, and after bone marrow transplantation.

Original languageEnglish
Pages (from-to)17-30
Number of pages14
JournalBlood Cells
Issue number1-2
StatePublished - 1987
Externally publishedYes


Dive into the research topics of 'Recombinant human granulocyte-colony stimulating factor: In vitro and in vivo effects on myelopoiesis'. Together they form a unique fingerprint.

Cite this